CTOs on the Move

Amarillo Biosciences

www.amarbio.com

 
Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.amarbio.com
  • 800 SW 9th Ave
    Amarillo, TX USA 79101
  • Phone: 806.376.1741

Executives

Name Title Contact Details

Funding

Amarillo Biosciences raised $20M on 05/03/2021

Similar Companies

Bracco Diagnostics

Established in August 1994, Bracco Diagnostics Inc. develops and markets a wide range of diagnostic imaging agents in the U.S. Bracco products are currently used in conjunction with X-ray, CT, MRI, and nuclear medicine. Bracco Diagnostics Inc. is a

HealthChem Contract Services

HealthChem Contract Services is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nidek

NIDEK offers a wide array of equipment designed for the diagnosis and treatment of retinal diseases, glaucoma, and other vision-impairing afflictions.

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.